Dishman Carbogen Amcis Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ylpwu9c8w16ux0cpctof3w5d.pdf

Key Takeaways


France: The GMP Catalyst

Stephan Fritschi: "the GMP certificate is the basis and the fundament to successfully work on GMP products and GMP commercial production"

India CRAMS Turnaround

Harshil Dalal: "If you see historically we have done upwards of 35%, 40% EBITDA margins for that particular business. So as the revenues keep on increasing, obviously, the cost base has increased because of the improvements that we have done, but we do expect that the margin should move towards the 20%, 25% mark."

Carbogen Amcis: Development Strength & Client Trust

Stephan Fritschi: "Quality, reliability and how we approach our customers and projects. So these are key words what are important to our clients. When we start to work with the client, we establish a relationship with them, which is based on trust. And clients get confident that we succeed."

Cholesterol, Vitamin D & Netherlands


Margins, Costs & Balance Sheet

Harshil Dalal: "It was one of the best quarters for us, and this is the third consecutive quarter where I have been saying this. So we just expect the performance to keep on improving from here on in the same manner as the last 3 quarters have been."

New Geographies & Capabilities


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthLow double-digit growth targeted; 12–15% CAGR over medium termFY26 / 3–5 years
EBITDAINR 550–570 crores minimum, ~20% margin; INR 750 crores medium-termFY26 / 2–3 years
Finance cost reduction10–15% lower vs FY25FY26
Net debt reductionDecline by INR 100–200 crores annuallyOngoing
French entity revenueDouble from EUR 8.6 million baseFY26
French entity breakevenOperating breakeven targeted; worst case at EUR 15–16 million revenueNot specified
India assets peak revenueINR 800 crores with all units running2–3 years
Bavla quarterly run-rateINR 100 crores per quarterFY26
ROCEDouble-digit3 years
CAPEXEUR 25–30 million (~INR 250–300 crores)FY26
Swiss expansion operationalBigger reactors and new capabilities for Japanese client2027

Key Metrics

MetricQ4 FY25
Revenue from operations₹2,711 cr for full FY25, +3.7% YoY; Q4 grew 9.4% YoY
EBITDA₹153 cr in Q4, vs ₹63.4 cr in Q4 FY24; full FY25 ₹472 cr vs reported ₹296 cr in FY24
EBITDA margin21.4% in Q4; full FY25 17.4%
Profit before tax₹27.7 cr in Q4; full FY25 ₹19.3 cr
Finance cost₹42 cr in Q4, down from ₹48 cr in previous quarter; expected 10–15% lower in FY26
Net debt₹157 cr as of Mar 31, 2025, down from ₹163 cr as of Mar 31, 2024
Carbogen Amcis CRAMS revenue₹489 cr in Q4, +9% YoY; full FY25 ₹2,003 cr vs ₹1,953 cr in FY24
Carbogen Amcis CRAMS EBITDA margin~25% in Q4 vs 15.6% in Q4 FY24; full FY25 19.7%
Cholesterol and Vitamin D analogues revenue₹121 cr in Q4 vs ₹91 cr in Q4 FY24; full FY25 ₹305 cr
Cholesterol and Vitamin D analogues EBITDA margin10.3% for full FY25 vs 17.8% in FY24
India CRAMS revenue₹80 cr in Q4; full FY25 ₹290 cr, +35% YoY
India CRAMS EBITDA margin17.3% in Q4 vs 5.2% in Q4 FY24; full FY25 13%
Quats and Generics revenue₹113 cr for full FY25, flattish vs ₹115 cr in FY24
French entity revenue€8.6 mn for full FY25; expected to double in FY26
French entity EBITDA loss€6.5 mn for full FY25
FY26 EBITDA target₹550–570 cr, targeting ~20% margin
Revenue CAGR expectation12–15% over next 3–5 years
India assets peak revenue potential~₹800 cr with all units running
Phase III late-stage projects14, down from 16 during the year
FY26 CAPEX guidance₹250–300 cr (€25–30 mn), including ~₹170–180 cr maintenance CAPEX